PJP vs. IYH: Which Healthcare ETF Is the Better Buy?

The key market takeaway is that the apparent diversification premium in IYH is smaller than advertised: both vehicles are effectively a leveraged vote on the same mega-cap pharma complex, with the rest of the basket acting more like a volatility dampener than a true diversifier. That matters because if leadership stays narrow, the cheapest way to express the trade is likely the individual names, not the ETF wrapper; if leadership broadens to devices, services, or managed care, PJP’s concentration becomes a liability while IYH’s hidden exposure mix helps it absorb the rotation.

The near-term risk is factor reversal rather than company-specific deterioration. PJP’s recent outperformance leaves it more vulnerable to mean reversion if the market starts paying for breadth, fee drag, or lower tracking error instead of pure pharma beta; in that scenario, IYH should outperform over the next 1-3 months even if healthcare as a sector is flat. Over 6-18 months, both funds remain highly sensitive to the same handful of names, so any earnings miss, litigation headline, or pricing-policy shock in LLY/ABBV/JNJ would still dominate ETF returns.

The contrarian point is that investors may be overpaying for “active-looking” concentration in PJP when the actual upside is already captured in the same three stocks. The more interesting relative-value setup is not outright bullish healthcare, but a rotation trade: if the current pharma strength pauses, the cheaper, higher-yielding, broader fund should close some of the performance gap. Falsifier: another quarter of LLY/ABBV/JNJ leadership with no breadth expansion, which would keep PJP’s momentum intact and punish any mean-reversion short.